Rohan Kumar is Laboratory Analyst at CS Analytical.

Rohan Kumar

medical concept background | Image Credit: ©ballykdy -stock.adobe.com


 spoke with Rohan Kumar, laboratory analyst at CS Analytical, to find out more about sustainability in pharmaceutical packaging and how companies can improve their efforts to ensure a sustainable future. Kumar works in contract package testing conducted within a broader package qualification strategy and will be participating in the Quick Fire session, “

Building a Sustainable Future for Pharmaceutical Packaging

”, at INTERPHEX in New York on Wednesday, April 22 at 2:30PM.

PharmTech:What are the current gaps in sustainability that occur in pharmaceutical packaging?

 I think the biggest gaps in sustainability stem from a ‘this is how it’s always been done’ mindset. While consistency and reliability are arguable some of the most important factors when making drug products, I think it is important that we distinguish [which] areas demand the most scrutiny and [which ones] not as much so. For example, conscious decisions to take the lifecycle management of a pre-filled syringe carton during initial design can have downstream long-term savings in materials, emissions, and capital.

What can pharmaceutical companies due to improve sustainability with their packaging materials?

The biggest thing I think pharmaceutical companies can implement is keeping sustainability in the picture from day one. Once a packaging design enters initial manufacturing, making changes become increasingly difficult as production ramps up. As such, proactively trying to make packaging more sustainable, while not impossible, ends up being a harder than expected task as it may also require revalidating systems. I am a firm believer that patient safety should always be the number one priority in this broader industry but that doesn’t mean that sustainability has to be an afterthought.

Are regulators pushing for more sustainable packaging?

Short answer is yes. There is currently a US Pharmacopeia subcommittee focusing on sustainability as well as government Extended Producer Responsibility (EPRs) that are now in place in a few states that are starting to drive the push towards sustainable packaging. However, the big caveat here is that the biggest hurdle here is data, and that data can only be provided by the manufacturers themselves. As such, it is important that more manufacturers and producers take the initiative to drive the regulatory change towards more sustainable packaging rather than waiting for it to happen.

Which packaging materials for solid dosage products are best for the environment?

For large-molecule products? Deciding on the choice of packaging materials for any drug product (solid oral dose, parenteral, biologics) is a nuanced question that usually requires an individualized approach based on the specific drug itself. Factors like light sensitivity, product acidity, reactivity, and many more can impact the choice of packaging. As such, it is hard to provide a one-material-fits-all recommendation even when considering drugs of the same format. Nonetheless, in my experience, the biggest areas that should see material changes are for those larger biologic products. The usage of recycled materials in autoinjector housing or vial caps, while small, are changes that can be made now that have no impact on the drug itself. For small-molecule drugs, HDPE and polypropylene are common choices. While alternative plastics are being developed, they have not yet been fully demonstrated to be as chemically non-reactive for widespread use. Improvements to the overall supply chain, pack out, and testing process can still have noticeable impacts.

Are there enough options in the packaging materials markets for pharmaceutical companies to choose from? What does the supply chain look like?

There are a wide range of options in packaging materials for pharmaceutical companies to choose from. The current barriers to implementation more so stem from cautious practices and a lack of precedent. From a supply chain perspective, things like smart shippers and systematic QR codes that can share digital information are improvements that can help optimization, which ultimately reduces emissions and the overall environmental burden.

Articles

Sustainability gaps in pharma packaging largely reflect entrenched practices and insufficient lifecycle thinking during early design. Integrating sustainability from day one is emphasized, since post-launch changes can trigger revalidation and become operationally prohibitive despite maintaining patient safety primacy. Regulatory momentum is increasing through USP activity and state-level Extended Producer Responsibility, but progress is constrained by manufacturer-generated data availability. Material selection remains product-specific, driven by stability and compatibility requirements, with near-term opportunities in biologics devices and supply-chain optimization.

Rohan Kumar, laboratory analyst at CS Analytical, discusses how sustainability in pharmaceutical packaging can be improved.